Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer

Published:2020-10-05 Issue:10 Volume:3 Page:e2013770
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Wang Zhijie¹,Ying Jianming²,Xu Jiachen¹,Yuan Pei²,Duan Jianchun¹,Bai Hua¹,Guo Changyuan²,Li Lin²,Yang Zhenlin³,Wan Rui¹,Fei Kailun¹,Zhao Zhe¹,Du Xinyang¹,Zhao Junhui⁴,Lv Ning²,Wang Jie¹

Affiliation:

1. Department of Medical Oncology, State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China

2. Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China

3. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

4. Department of Medical Oncology, Affiliated Hospital of Qinghai University, Qinghai, China

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2771218/wang_2020_oi_200519_1601054754.33784.pdf

Reference38 articles.

1. Cell-free circulating tumor DNA in plasma/serum of non–small cell lung cancer.;Nie;Tumour Biol,2015

2. Pembrolizumab for the treatment of non–small cell lung cancer.;Garon;N Engl J Med,2015

3. Atezolizumab versus docetaxel for patients with previously treated non–small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.;Fehrenbacher;Lancet,2016

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.;Brahmer;N Engl J Med,2015